Literature DB >> 24173658

An audit of first afebrile seizure management in an Irish tertiary pediatric setting.

Michael Boyle1, Joseph Chukwu, Mary Boyle, Ann Connolly, David Webb.   

Abstract

UNLABELLED: The objective of this study was to compare the first afebrile seizure management with internationally recognized standards in an Irish tertiary pediatric setting. Twenty-one management standards were derived from a combination of British (NICE 2004) and North American (AAN 2003) guidelines. Cases of first afebrile seizure presenting to a pediatric emergency department between July 2007 and June 2010 were assessed against the standards. On completion, the standards developed were presented to the relevant stakeholders, a nurse-developed parental advice sheet was introduced, and a re-audit was performed from July 2010 to June 2011. Forty children were identified in the initial audit period (A1) and 41 over the re-audit (A2). No case achieved full compliance with the devised standards in the audit period. A median compliance score of 15 (range 5-20) was achieved in A1 and 17 (range 11-21) in A2 [mean rank 31.93 versus 49.85; p(1,1) < 0.0001]. Optimal compliance (total score of ≥17) with devised standards was achieved in 6/40 patients in A1 and in 21/41 patients in A2 [χ (2) = 11.95; p(1,1) = 0.001].
CONCLUSION: We demonstrated an initial lack of compliance with international guidelines on management of a common medical presentation, first afebrile seizure, and demonstrated that improvements can be achieved by identification of appropriate standards and critical appraisal of the compliance with these standards through both formal and informal education.

Entities:  

Mesh:

Year:  2013        PMID: 24173658     DOI: 10.1007/s00431-013-2180-7

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  15 in total

Review 1.  Less testing is needed in the emergency room after a first afebrile seizure.

Authors:  John M Freeman
Journal:  Pediatrics       Date:  2003-01       Impact factor: 7.124

Review 2.  An evaluation of Medline published paediatric audits from 1966 to 1999.

Authors:  Clodagh Sheila O'Gorman; Yasir Ziedan; Michael Brendan O'Neill
Journal:  Arch Dis Child       Date:  2006-05-31       Impact factor: 3.791

3.  A pallid paroxysmal event in children: it is vagal anoxic seizure, it is treatable, and it is not "epilepsy".

Authors:  Jose Ramet
Journal:  Eur J Pediatr       Date:  2011-08-17       Impact factor: 3.183

4.  Interobserver agreement in the assessment of clinical findings in children with first unprovoked seizures.

Authors:  Peter S Dayan; Kathleen Lillis; Jonathan Bennett; Gregory Conners; Pam Bailey; James Callahan; Cidgem Akman; Neil Feldstein; W Allen Hauser; Nathan Kuppermann
Journal:  Pediatrics       Date:  2011-04-11       Impact factor: 7.124

5.  Afebrile pediatric seizures.

Authors:  Ghazala Q Sharieff; Phyllis L Hendry
Journal:  Emerg Med Clin North Am       Date:  2011-02       Impact factor: 2.264

6.  Role of head computed tomography in the evaluation of children admitted to the paediatric intensive care unit with new-onset seizure.

Authors:  Tanya Bautovich; Andrew Numa
Journal:  Emerg Med Australas       Date:  2012-04-18       Impact factor: 2.151

7.  An audit of paediatric epilepsy care.

Authors:  D W Webb; H Coleman; A Fielder; C R Kennedy
Journal:  Arch Dis Child       Date:  1998-08       Impact factor: 3.791

8.  Inpatient brain MRI for new-onset seizures: utility and cost effectiveness.

Authors:  Daniel A Rauch; Emily Carr; John Harrington
Journal:  Clin Pediatr (Phila)       Date:  2008-02-29       Impact factor: 1.168

9.  The role of emergent neuroimaging in children with new-onset afebrile seizures.

Authors:  Sujit Sharma; James J Riviello; Marvin B Harper; Marc N Baskin
Journal:  Pediatrics       Date:  2003-01       Impact factor: 7.124

Review 10.  [Management of patients after a first seizure].

Authors:  G Soto-Ares; P Jissendi Tchofo; W Szurhaj; G Trehan; X Leclerc
Journal:  J Neuroradiol       Date:  2004-09       Impact factor: 3.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.